Wound-care product from Osiris shows positive trial results

08/14/2013 | Reuters

Osiris Therapeutics reported that its Grafix wound-care product, which releases stem cells straight to the wound site to allow tissue regeneration, demonstrated effectiveness in treating patients with diabetic foot ulcers in a postmarket study. The study found that complete wound closure was achieved in 62% of patients who were treated with Grafix, compared with 21% of those who received traditional therapy.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI